Shares of TG Therapeutics (NASDAQ: TGTX) gained over 60% in today’s session. This can be attributed to discussions between the company and the FDA about labeling for its multiple sclerosis therapy ublituximab.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Although ublituximab has not been approved yet, this is likely a good sign that approval chances are favorable.
Is TGTX Stock a Good Buy?
TGTX stock has a Moderate Buy consensus rating based on two Buys assigned in the past three months. The average TGTX stock price target of $18 implies 117.13% upside potential.
